New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
15:32 EDTREN, TWER, FST, TRAK, CIM, RAX, VTR, JOBS, MR, ICPT, CZR, GSAT, OPK, NUANNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Ventas (VTR), consensus $1.09; Nuance Communications (NUAN), consensus 27c; Intercept Pharmaceuticals (ICPT), consensus (12c); Rackspace Hosting (RAX), consensus 16c; Opko Health (OPK), consensus (9c); Mindray Medical (MR), consensus 54c; Chimera Investment (CIM), consensus 9c; Globalstar (GSAT), one estimate (4c); 51job (JOBS), consensus 32c; Dealertrack Technologies (TRAK), consensus 373c; Caesars Entertainment (CZR), consensus ($1.19); Towerstream (TWER), consensus (10c); Resolute Energy (REN), consensus 1c; Forest Oil (FST), consensus (2c).
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 19, 2015
10:25 EDTNUANOptions with decreasing implied volatility
Subscribe for More Information
November 18, 2015
07:42 EDTICPTIntercept PBC treatment revenue likely to beat expectations, says Oppenheimer
Subscribe for More Information
November 17, 2015
12:46 EDTNUANOn The Fly: Top stock stories at midday
Stocks on Wall Street were higher at midday after better than expected earnings from Wal-Mart (WMT) and Home Depot (HD) helped the Dow build on yesterday's gains. The market also received a boost from an in-line consumer prices report, which may give the Fed the ammunition it needs to begin to raising interest rates from their record-low levels. ECONOMIC EVENTS: In the U.S., the consumer price index rose 0.2% in October, as expected. When food and energy prices are stripped out, the "core" CPI also rose 0.2%, also matching the consensus forecast. Industrial production slid 0.2% in October, versus expectations for it to have risen 0.1%. Capacity utilization came in as expected at 77.5%. NAHB's home builder sentiment index fell 3 points to 62 in November, versus expectations for a reading of 64. COMPANY NEWS: Shares of Wal-Mart advanced nearly 5% after the world's largest retailer reported better than expected quarterly earnings and gave a fiscal year profit outlook that was higher than expected at the midpoint of the company's range. As part of its report, Wal-Mart noted that comp sales at Walmart U.S. rose 1.5% in the quarter compared to last year, marking the fifth consecutive quarter of positive comparable sales growth. Another retail giant and fellow Dow member, Home Depot, gained more than 3.5%. Missing out on the retail rally, however, was Dick's Sporting Good (DKS), which tumbled over 9.5% after giving guidance for the fourth quarter and fiscal 2015 that both missed consensus estimates. MAJOR MOVERS: Among the notable gainers was Nuance (NUAN), which rallied 17% after analysts raised their price targets on the company's stock following upbeat fourth quarter earnings. Also higher was TJX (TJX), which gained 4% after reporting quarterly earnings and guiding for the fourth quarter and fiscal 2016. Among the notable losers was SunEdison (SUNE), which fell 21% after Deutsche Bank lowered its price target on the company's shares to $16 from $28. Also lower was Urban Outfitters (URBN), which fell 8% after no fewer than three analyst downgraded the company's shares following its Q3 earnings report. INDEXES: Near midday, the Dow was up 39.99, or 0.23%, to 17,523.00, the Nasdaq was up 17.91, or 0.36%, to 5,002.53, and the S&P 500 was up 3.54, or 0.17%, to 2,056.73.
10:48 EDTNUANNuance rises after earnings as analysts point to bookings as positive sign
Shares of Nuance Communications (NUAN) climbed in morning trading after analysts from Deutsche Bank and Oppenheimer raised their price targets on the company following upbeat fourth quarter earnings. WHAT'S NEW: After the market close yesterday, Nuance reported Q4 earnings per share of 41c, beating analyst estimates of 35c, on revenue of $504.1M, just short of consensus $507.84M. The company provided guidance for fiscal 2016, saying it expects earnings per share for the year in the range of $1.35-$1.45 on revenue of $1.95B-$2B. Nuance also said it expects first quarter EPS of 31c-33c on revenue of $477.8M-$489.8M. WHAT'S NOTABLE: In the same press release, Nuance chief financial officer Dan Tempesta said that the company has made "substantial progress" on its company-wide transformation project. "We expect to continue our improvements in financial performance and lead the company to improved growth in 2016 and beyond," Tempesta said. STREET RESEARCH: Following the quarterly report, Deutsche Bank analyst Nandan Amladi maintained a Buy rating on the company's stock and raised its price target to $30 from $25, citing greater visibility from recurring revenue. Amladi said that Nuance had a "robust" finish to fiscal 2015 and that bookings and recurring revenue metrics were stronger than traditional licenses. The analyst added that the company's outlook leaves some headroom for upside and that its buyback activity should continue its "pronounced" pace heading into FY16. In addition, Oppenheimer analyst Shaul Eyal maintained an Outperform rating on Nuance and raised the price target on the company's shares to $26 from $22, saying that the company's shift towards a more software-as-a-service focused business model shows positive indications. Eyal added that the company's fundamentals are improving and that EPS accretion is supported by an ongoing share repurchase and cost containment measures. PRICE ACTION: In morning trading, Nuance rallied 14.5% to $19.53. OTHERS TO WATCH: Philips (PHG), which reached a collaboration agreement with Nuance a month ago to provide Nuance users its PowerScribe 360 software, was up 1.4% in morning trading.
10:02 EDTNUANHigh option volume stocks
Subscribe for More Information
09:15 EDTNUANOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.1%... Cheetah Mobile (CMCM), up 7.7%... Eros International (EROS), up 12.8%... Home Depot (HD), up 3.1%...Wal-Mart (WMT), up 2.2%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 14.8% after announcing Phase 1 study results for the company's oral formulation of OCR-002... Fitbit (FIT), up 2.4% after being upgraded to Buy from Neutral at BofA/Merrill. DOWN AFTER EARNINGS: Dicks Sporting Goods (DKS), down 15.4%... Urban Outfitters (URBN), down 12.8%. ALSO LOWER: Osiris Therapeutics (OSIR), up 25.5% after being downgraded to Sell from Hold at Brean Capital... Angie's List (ANGI), down 8.7% after board unanimously determines not to pursue IAC (IACI) proposal... Clovis Oncology (CLVS), down 4.1% after receiving downgrades from Goldman and WallachBeth... Chesapeake Energy (CHK), down 2.5% after being downgraded to Neutral from Buy at Sterne Agee CRT... Cooper Companies (COO), down 2% after being downgraded to Market Perform from Outperform at Wells Fargo.
08:14 EDTVTRRBC Capital to hold events at NAREIT
RBC Capital Events being held at NAREIT in Las Vegas on November 17-18.
07:55 EDTNUANNuance price target raised to $26 from $22 at Oppenheimer
Subscribe for More Information
06:36 EDTNUANNuance price target raised to $30 from $25 at Deutsche Bank
Subscribe for More Information
November 16, 2015
18:26 EDTNUANOn The Fly: After Hours Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.5%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 26.6% after announcing Phase 1 study results for the company's oral formulation of OCR-002. DOWN AFTER EARNINGS: Urban Outfitters (URBN), down 11.5%... Agilent (A), down 1.3%. ALSO LOWER: Wayfair (W), down 2% after Bloomberg reported that Whitney Tilson said that Wayfair is currently his largest short.
16:15 EDTNUANNuance sees Q1 EPS 31c-33c, consensus 31c
Sees Q1 GAAP revenue $477.8M-$489.8M, consensus $490.62M. Sees Q1 Non-GAAP revenue $486M-$498M.
16:13 EDTNUANNuance sees FY16 EPS $1.35-$1.45 consensus $1.38
Subscribe for More Information
16:04 EDTNUANNuance reports Q4 EPS 41c, consensus 35c
Reports Q4 revenue $504.1M, consensus $507.84M. In the fourth quarter of fiscal 2015, Nuance reported GAAP revenue of $504.1M up from $502.3M a year ago. Nuance reported non-GAAP revenue of $513.3M, which includes $9.2M of revenue lost to accounting treatment in conjunction with acquisitions, compared to $520.3M in the fourth quarter of fiscal 2014. Fourth quarter 2015 revenue was negatively affected by currency fluctuations as well. If fourth quarter 2014 currency rates were applied to fourth quarter 2015 non-GAAP revenue, Nuance would have achieved approximately 1% organic non-GAAP revenue growth for the quarter. In the fourth quarter of 2015, total recurring revenue was $347M and represented 68% of total non-GAAP revenue, compared to $325.7M and 63% a year ago. In the fourth quarter of fiscal 2015, Nuance reported net new bookings of $357.4M, up 8.7% from $328.8M a year ago. If fourth quarter 2014 currency rates were applied to Nuance's fourth quarter 2015, net new bookings would have been up 12% from a year ago.
15:53 EDTRAXJANA Partners reduces stakes in Rackspace, Qualcomm
JANA Partners gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Mattel (MAT), Zoetis (ZTS), and Aramark (ARMK). INCREASED STAKES: ConAgra Foods (CAG). DECREASED STAKES: Rackspace (RAX), Qualcomm (QCOM), Time Warner (TWX), Starz (STRZA), and Lions Gate (LGF). LIQUIDATED STAKES: Johnson Controls (JCI), Precision Castparts (PCP), AerCap Holdings (AER), United Rentals (URI), and HD Supply Holdings (HDS).
15:02 EDTNUANNotable companies reporting after market close
Subscribe for More Information
13:38 EDTNUANNuance technical comments ahead of results
The stock has been trading in a range since September of this year that is defined largely by a low at $16 and a high at $17.75. If the news is bullish, there could be a breakout above the top of the range. Next resistance levels above $17.75 are at $18.49, $18.96, which is the 52-week high, and $19.39. If the news is a negative surprise, there could be a break of the low of the range. Next supports below $16 would be at $15.21, $14.60, and $14.
11:33 EDTOPKOPKO Health licensee Tesaro announces launch of Varubi in the U.S.
Subscribe for More Information
10:25 EDTRAXOptions with decreasing implied volatility
Subscribe for More Information
November 15, 2015
15:08 EDTICPTIntercept reports analysis of Phase 3 obeticholic acid study, other data
Intercept announced results from three studies in primary biliary cirrhosis, recently renamed primary biliary cholangitis, for presentation at the American Academy for the Study of Liver Diseases annual meeting. The studies evaluate investigational use of obeticholic acid, Intercept's lead farnesoid X receptor agonist. In a presentation titled, "Clinical Epidemiology of Primary Biliary Cirrhosis based on a Large U.S. Laboratory Database: Incidence and Trends in Serum Alkaline Phosphatase," an analysis of a clinical database of more than 575,000 patients who received an anti-mitochondrial antibody test showed that, of those patients, 6,107 were classified as having probable PBC based on a positive AMA test and ALP greater than the upper limit of normal at any time prior to AMA testing or up to one month following AMA testing. The study found that 69% of those likely PBC patients continued to have elevated ALP two years after the first positive AMA test. Meanwhile, a presentation titled "A Trial-Based Model of Liver Transplant and Liver-Related Death in Patients with Primary Biliary Cirrhosis" includes an analysis of data from the Phase 3 POISE trial of OCA in PBC using the UK-PBC predictive model of transplant-free survival based on ALP, bilirubin, alanine transaminase, albumin and platelet count. Risk was assessed at 5, 10 and 15 years based on a 12-month change from baseline in patients treated with OCA plus or minus ursodiol or placebo plus or minus ursodiol at the end of the POISE study. The UK-PBC risk algorithm showed a significantly lower risk of liver transplant or liver-related death in OCA-treated patients compared to placebo. Lastly, a presentation titled "Physician versus Patient Perceptions of Medical Care Quality in Primary Biliary Cirrhosis" showed that patients may not be properly informed about their ALP scores and the nature of PBC symptoms.
14:38 EDTICPTIntercept reports analyses of OCA in fatty liver patients
Intercept Pharmaceuticals announced new results from the non-invasive evaluation of liver fibrosis in patients from the FLINT trial of obeticholic acid, or OCA, for the treatment of nonalcoholic steatohepatitis, or NASH. In the trial, treatment with once daily 25 mg OCA was shown to reverse fibrosis in a "significant proportion" of biopsy-proven NASH patients, as observed by repeat liver biopsy at the end of the double-blind treatment phase at week 72, according to the company. Post-hoc analysis evaluated the early predictive value of three known non-invasive fibrosis tests -- FIB-4, APRI and NFS -- in identifying patients who experienced improvement in fibrosis. Each was assessed at baseline and over the course of treatment and then correlated with histologic changes observed in the OCA and placebo patients. The analysis demonstrated that OCA treatment of NASH patients led to a statistically significant decrease in FIB-4 from baseline as compared to placebo. Further, a decline in FIB-4 of 10% after 24 weeks of treatment predicted improvement in fibrosis by at least one stage as assessed by biopsy at 72 weeks, according to Intercept. Similarly, OCA-treated patients experienced a significant decrease in APRI as compared to placebo, and a 34% reduction in APRI at 24 weeks predicted improvement in fibrosis by at least one stage at 72 weeks. On average, OCA treatment reduced the FIB-4 score to less than 1.3 and the APRI score to less than 0.5, the respective cut-off values associated with advanced fibrosis, while placebo patients remained above these cut-offs. While NFS declined in the OCA-treated patients and increased in the placebo patients, it did not appear to be sensitive to changes in fibrosis, the company said.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use